Truist raised the firm’s price target on Mersana Therapeutics (MRSN) to $10 from $9 and keeps a Buy rating on the shares after its Q1 results. The firm is positive on the company’s Emi-Le’s improving overall response ratio in B7-H7 high patients as well as Mersana beening able to push the dose higher with prophylactic tox management and step dosing, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRSN:
- Mersana Therapeutics Reports Promising Clinical Advances
- Mersana Therapeutics’ Earnings Call: Mixed Outlook with Clinical Gains
- Positive Developments in Mersana Therapeutics’ TNBC Trials and Stable Financial Position Support Buy Rating
- Promising Clinical Trial Results and Strategic Development Drive Buy Rating for Mersana Therapeutics
- Mersana Therapeutics reports Q1 EPS (19c), consensus (19c)